Market Research Industry Reports

Payer Insights: RA [2016]: Bulletin #3


This edition presents payer views on recent developments in the rheumatoid arthritis (RA) market. Topics include; recent approvals for biosimilar rituximab products in Europe Celltrion/Mundipharmas Truxima (CT-P10) and Sandoz (Novartis) Rixathon; approvals of biosimilar anti-TNF therapies in the EU/US with Merck & Co. launching Renflexis (biosimilar infliximab) in the US at a 35 percent discount to the wholesale acquisition cost (WAC) of Remicade; and the approval of Regeneron/Sanofis interleukin-6 (IL-6) inhibitor Kevzara (sarilumab) in the US at a 30 percent discount to branded market leaders Humira and Enbrel.

Business Questions:

How do payers view the recently approved biosimilars of rituximab?
How will the availability of biosimilar rituximab impact the usage of the drug in RA; will rituximab be used in earlier treatment settings?
On what factors will the switch from branded to biosimilar rituximab depend?
How is the launch of biosimilar adalimumab expected to alter the RA treatment algorithm?
What level of discount do payers demand in order to facilitate market penetration of biosimilar adalimumab?
How will the 35 percent discount on biosimilar infliximab alter the RA treatment paradigm in the US?
How will biosimilars be positioned in the formulary for the treatment of RA?
What factors will drive the acceptance of biosimilars by payers?
How will payers manage the use of biosimilars in treatment-nave and treatment-experienced patients?
How do payers view the pricing strategy for Kevzara and where will it be positioned in the formulary?
How do payers view the anti-IL-6 drug class for the treatment of RA and how do they compare with oral JAK inhibitors?
What drug class will payers prefer to contract for the treatment of RA and why?
How is the RA treatment paradigm expected to evolve in the future?

Biosimilars: US Payer Perspectives (2018)

US payers eye European biologics market with envyBiosimilars may be a roaring success in Europe but the picture in the US couldnt be more different. Once hailed as a solution

USD 2495View Report

Biosimilars: EU Payer Perspectives

Leading European payer experts reveal the real impact of biosimilars over the last 12 monthsKeeping track of the dynamics and nuances of the biosimilars market is critical not least

USD 2495View Report

Payer Insights: RA [2016]: Bulletin #2

This edition presents payer views on recent developments in the rheumatoid arthritis (RA) market. Topics include; recent positive opinion from the European Medicines Agency (EMA) for Regeneron/Sanofis Kevzara (sarilumab); recent

USD 1045View Report

Payer Insights: MS [2016]: Bulletin #3

Topics covered in this update include: payers approaches to the reimbursement of Ocrevus (ocrelizumab; Roche/Biogen) for relapsing remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS); the impact of

USD 1045View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)


  • PDF    USD 1045
  • Enterprise Wide Licence    USD 2575
$ 1045

Reports Details

Published Date : Aug 2017
Country :Global
Category :Healthcare
Publisher :FirstWord Dossier
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE


We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube